Corrigendum to "Estimation of the inhibiting impact of abiraterone D4A metabolite on human steroid 21-monooxygenase (CYP21A2)" [Steroids 154 (2020) 108528]. Masamrekh R, Filippova T, Haurychenka Y, Shcherbakov K, Veselovsky A, Strushkevich N, Shkel T, Gilep A, Usanov S, Shumyantseva V, Kuzikov A.Steroids. 2020 Sep;161:108674. doi: 10.1016/j.steroids.2020.108674. Epub 2020 Jun 10.PMID: 32534271 

Estimation of the inhibiting impact of abiraterone D4A metabolite on human steroid 21-monooxygenase (CYP21A2). Masamrekh R, Filippova T, Haurychenka Y, Shcherbakov K, Veselovsky A, Strushkevich N, Shkel T, Gilep A, Usanov S, Shumyantseva V, Kuzikov A.Steroids. 2020 Feb;154:108528. doi: 10.1016/j.steroids.2019.108528. Epub 2019 Oct 31.PMID: 31678135

In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions. Masamrekh RA, Kuzikov AV, Haurychenka YI, Shcherbakov KA, Veselovsky AV, Filimonov DA, Dmitriev AV, Zavialova MG, Gilep AA, Shkel TV, Strushkevich NV, Usanov SA, Archakov AI, Shumyantseva VV.Fundam Clin Pharmacol. 2020 Feb;34(1):120-130. doi: 10.1111/fcp.12497. Epub 2019 Aug 5.PMID: 31286572

Hydroxylation of Antitubercular Drug Candidate, SQ109, by Mycobacterial Cytochrome P450. Bukhdruker S, Varaksa T, Grabovec I, Marin E, Shabunya P, Kadukova M, Grudinin S, Kavaleuski A, Gusach A, Gilep A, Borshchevskiy V, Strushkevich N.Int J Mol Sci. 2020 Oct 16;21(20):7683. doi: 10.3390/ijms21207683.PMID: 33081390